Quaternary Ammonium Compound Disinfectants Reduce Lupus-Associated Splenomegaly by Targeting Neutrophil Migration and T-Cell Fate

Leila Abdelhamid¹, Xavier Cabana-Puig¹, Qinghui Mu¹,², Maryam Moarefian³, Brianna Swartwout⁴, Kristin Eden¹, Prema Das¹, Ryan P. Seguin⁵, Libin Xu⁵, Sarah Lowen⁶, Mital Lavani⁶, Terry C. Hrubec¹,6*, Caroline N. Jones⁷,⁸* and Xin M. Luo¹*

¹ Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States, ² School of Medicine, Stanford University, Stanford, CA, United States, ³ Department of Mechanical Engineering, Virginia Tech, Blacksburg, VA, United States, ⁴ Translational Biology, Medicine and Health Graduate Program, Virginia Tech, Roanoke, VA, United States, ⁵ Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA, United States, ⁶ Department of Anatomical Sciences, Edward Via College of Osteopathic Medicine-Virginia Campus, Blacksburg, VA, United States, ⁷ Department of Biological Sciences, Virginia Tech, Blacksburg, VA, United States, ⁸ Department of Bioengineering, University of Texas, Dallas, TX, United States

Hypersensitivity reactions and immune dysregulation have been reported with the use of quaternary ammonium compound disinfectants (QACs). We hypothesized that QAC exposure would exacerbate autoimmunity associated with systemic lupus erythematosus (lupus). Surprisingly, however, we found that compared to QAC-free mice, ambient exposure of lupus-prone mice to QACs led to smaller spleens with no change in circulating autoantibodies or the severity of glomerulonephritis. This suggests that QACs may have immunosuppressive effects on lupus. Using a microfluidic device, we showed that ambient exposure to QACs reduced directional migration of bone marrow-derived neutrophils toward an inflammatory chemoattractant ex vivo. Consistent with this, we found decreased infiltration of neutrophils into the spleen. While bone marrow-derived neutrophils appeared to exhibit a pro-inflammatory profile, upregulated expression of PD-L1 was observed on neutrophils that infiltrated the spleen, which in turn interacted with PD-1 on T cells and modulated their fate. Specifically, QAC exposure hindered activation of splenic T cells and increased apoptosis of effector T-cell populations. Collectively, these results suggest that ambient QAC exposure decreases lupus-associated splenomegaly likely through neutrophil-mediated toning of T-cell activation and/or apoptosis. However, our findings also indicate that even ambient exposure could alter immune cell phenotypes, functions, and their fate. Further investigations on how QACs affect immunity under steady-state conditions are warranted.

Keywords: lupus (SLE), neutrophil, quaternary ammonium compound (QAC), autoimmunity, splenomegaly, T cells
INTRODUCTION

Systemic lupus erythematosus (SLE or lupus) is a complex multisystem autoimmune disorder with diverse clinical manifestations (1–3), with enlargement of lymphoid organs as one of the first symptoms (4–6). Genetic mutations can initiate the progression of SLE in susceptible individuals (7–10). However, lupus manifestations are very heterogenic and can vary from one individual to another (11, 12). Aside from genetic factors, this heterogeneity is strongly influenced by environmental factors (13, 14) that could drive the progression of SLE in susceptible individuals and shape treatment outcomes. In this study, we sought to better understand how environmental factors influence the complex pathogenesis of SLE.

Quaternary ammonium compounds (QACs) are ubiquitous biocides (15), antiseptics (16), and widely used surface disinfectants (16). Exposure to QACs is associated with development of topical hypersensitivity (17) and asthma (18) especially in hospital settings (19). Although the exact mechanisms of how QACs modulate immune cell responses are unclear, QAC-induced allergic responses have been attributed to abrogated type 2 innate lymphoid cell responses (20). To understand the possible effects of QACs on innate immunity, we investigated how QACs affected murine macrophages in vitro. Exposure to QACs increased the production of pro-inflammatory cytokines but paradoxically reduced the phagocytic potential of murine macrophages (21). Interestingly, effective macrophage responses are required for clearance of autoantigens; and impaired macrophages responses could contribute to the development of autoimmune conditions (22). These findings raised the question of whether QAC exposure would cause immune dysregulation and affect systemic autoimmunity such as lupus. We hypothesized that QACs would exacerbate lupus.

Here, we delineate the effects of ambient exposure to QAC disinfectants on the progression of lupus-like disease in the MRL/lpr mouse model. We show that ambient QAC exposure mitigates lupus-associated splenomegaly, and propose abnormal neutrophil migration and T-cell dysregulation as potential mechanisms behind this surprising finding.

MATERIALS AND METHODS

Animal Housing
MRL/lpr mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained in a specific pathogen-free environment in an AAALAC accredited animal facilities at Virginia Tech. All procedures were carried out according to an approved IACUC protocol 17-128. Due to the challenge of eliminating QACs once contaminated, QAC-free and exposed mice were housed in separate vivaria (23, 24). In addition, QAC-free mice were housed in disposable cages to avoid QAC contamination during cage wash, whereas mice with ambient exposure to QAC were housed in reusable polycarbonate cages. With the exception of disinfectants, all other factors, including diet (hormone-free NIH-31 Modified 6% Mouse/Rat Diet), bedding (shredded paper), and light cycle (12-h light/dark), were consistent among the facilities. Food and water were provided ad libitum. QAC-based disinfectants CP-64 or Labsan 256 were used under QAC-exposed conditions, while ethanol was used in the QAC-free environment. To generate QAC-free mice, MRL/lpr mice were bred for at least 2 generations in the QAC-free facility (IDU) to eliminate any contamination from vendor sources (23, 25). QAC-exposed mice were exposed either via cage wash only (Phase IV, uncontrolled environment) or through the use of a QAC-based disinfectant inside the room (ILSB). Only female mice were analyzed as lupus has a strong sex bias (26–28).

Measurement of QAC Levels
Multiple cages were sequentially washed with 50 ml LC/MS-grade methanol. QAC residues from the samples were then extracted using Folch solution (chloroform/methanol = 2/1). After extraction, the samples were re-constituted in the LC solvent and then analyzed by UPLC-MS/MS (29). QAC-equivalent units per mouse cage, which were variable due to the nature of ambient exposure, were calculated and presented in Table S1.

Isolation of Bone Marrow (BM)-Derived Neutrophils
BM isolation was performed as previously described (30, 31) with minor modifications. The procedures were performed at room temperature instead of 4°C, as the latter might interfere with neutrophil migration and chemotaxis assays. In addition, we proceeded to enrich neutrophils without red blood cell lysis due to the same concern. A Mouse Neutrophil Enrichment Kit (StemCell Technologies, Vancouver, BC) was used following the manufacturer’s procedures.

Neutrophil Chemotaxis Assay
A Microfluidic Competitive Chemotaxis-Chip (μC3) device (Figure S1) was modified from our previous design (32). Device fabrication was achieved with 50 μl fibronectin (Sigma-Aldrich, St. Louis, MO) at a concentration of 10 μg/ml following our previously reported procedures (32) to recapitulate the extracellular matrix needed for neutrophil adhesion to the device surface (32, 33). The chemotactrant, leukotriene B4 (LTB4; Cayman Chemical, Ann Arbor, MI), diluted in RPMI supplemented with 10% fetal bovine serum, was loaded into the chemotactrant reservoir at a clinically relevant concentration of 100 nM (32, 34). Time-lapse imaging experiments were performed as previously reported (32). Time-lapse image capture was performed with a NIS-elements (Nikon Inc., Melville, NY). Images were recorded using fluorescent and bright-field channels at 3-min intervals for 8 h. Image analysis was performed with ImageJ.

Isolation of Splenocytes and In Vitro Stimulation
Spleens were harvested aseptically and total splenocytes were isolated as we previously reported (30). To determine T cell proliferation and/or apoptosis potential, splenocytes were
stimulated with anti-CD3/anti-CD28 mouse monoclonal antibodies (eBioscience) following the manufacturer’s protocol with minor modifications. For proliferation analysis, splenocytes were initially stained with CellTrace™ CFSE Cell Proliferation Dye (Thermo Scientific). Briefly, 96-well plates were pre-coated overnight with 5 μg/ml anti-CD3ε at 4°C, then washed to remove unbound antibodies. CFSE-treated or untreated cell suspension were added at a cell density of 2 × 10^6 cells/ml in 100 μl/well, and a soluble anti-CD28 antibody was added at a concentration of 1 μg/ml. Cells were incubated at 37°C for 2 to 3 days then analyzed for proliferation or apoptosis using flow cytometry.

**Flow Cytometry**

Cells were initially blocked with anti-mouse CD16/32 (eBioscience) then stained with fluorochrome-conjugated antibodies following our previous procedures (30). Briefly, after blocking of Fc receptors, cells were stained with fluorochrome-conjugated antibodies on ice in the dark for 15 min. Exclusion of dead cells was achieved with Zombie Aqua (BioLegend) staining. For quantification of T cells in total splenocytes, the following anti-mouse antibodies were used: CD3-APC, CD4-PE-Cy7, CD8-PerCP-Cy5.5, CD44-PE, CD62L-APC-Cy7, and CD69-Pacific blue (BioLegend). The same panel of antibodies were used for in-vitro activated splenocytes. For analysis of apoptosis, FITC-Annexin V Apoptosis Detection Kit (BioLegend) was used together with propidium iodide according to the manufacturer’s procedures. Splenic Gr-1+ cells in the CD11b+CD11c+ myeloid population were analyzed using the following anti-mouse antibodies: CD11c-APC, CD11b-PerCP-Cy5, PD-L1-PE-Cy7 (BioLegend), and Gr-1-V540 (BD Bioscience). Analysis was performed with a BD FACSaria II flow cytometer (BD Biosciences). Flow cytometry data were analyzed with FlowJo.

**Immunohistochemistry (IHC)**

Splenic tissue embedding, cryosectioning and storage were performed as previously reported (30). Neutrophils were visualized with anti-mouse Ly6G-PE (BioLegend) and IHC was performed as previously described (30, 35). To visualize the interaction between neutrophils and T cells through PD-L1:PD-1 interaction, we used anti-mouse PD-L1-AF405 (R&D Systems) and anti-mouse PD-1-AF488, Ly6G-PE, and CD3-APC (Biolegend). Images were captured with a Zeiss LSM 880 confocal microscope. Image processing and quantification of the fluorescent intensity was performed with ImageJ and ZEN 2.1 Lite software.

**RNA Extraction and RT-qPCR**

Total RNA extraction from snap-frozen kidney and spleen tissues (pre-weighed), as well as enriched neutrophils, was performed as we previously reported (30). Briefly, samples were homogenized in Qiazol lysis reagent (Qiagen) using a bullet blender homogenizer (Next Advance, Troy, NY). Total RNA was extracted using RNeasy Plus Universal Kit (Qiagen) that also ensured gDNA elimination. All procedures were performed according to the manufacturer’s instructions. Reverse transcription (RT) was performed by using iScript™ Reverse Transcription Supermix (Bio-Rad). Quantitative PCR (qPCR) was performed with PowerUp™ SYBR® Green Master mix and an ABI 7500 Fast Real-Time PCR System (Applied Biosystems). Relative expression of different transcripts was calculated using the 2^−ΔΔCt method with 18S rRNA as the housekeeping gene. Data are shown as ΔCt values. Primer sequences for mouse IL-6, TNFα, IL-1β, BAFF, IL-6 receptor, gp-130 (IL-6 signaling transductor), PD-L1, CXCR4, and CXCR2 are shown in Table S2.

**ELISA**

Anti-double-stranded (ds)DNA IgG levels in diluted serum samples was determined following a previously reported ELISA assay (36). Total serum IgG levels were determined with a commercial kit (Bethyl Laboratories). Serum TNFα and IL-6 levels were measured with Biolegend’s ELISA MAX kits.

**Statistical Analysis**

Student’s t test was employed for the comparison between groups. Specifically, unpaired t test was used for the first experimental setting (see below for details); whereas paired t test was used for the second experimental setting since littermates were used to generate the two experimental groups. Asterisks were used to indicate significant differences (P < 0.05), and the unequal sign (≠) indicates nearly significant P-values (P < 0.10). All analyses were performed with Prism GraphPad.

**RESULTS**

**Reduced Lupus-Associated Splenomegaly With Ambient Exposure to QACs**

We had previously observed that QACs increased the production of pro-inflammatory cytokines from macrophages (21). Thus, we hypothesized that they would exacerbate autoimmunity and investigated whether ambient exposure to QACs in the form of a disinfectant would affect disease pathogenesis in lupus-prone MRL/lpr mice. We performed the study in two experimental settings to try to eliminate confounding variables generated from the fact that we had to house the QAC-free and QAC-exposed MRL/lpr littermates were used to generate the two experimental groups. Asterisks were used to indicate significant differences (P < 0.05), and the unequal sign (≠) indicates nearly significant P-values (P < 0.10). All analyses were performed with Prism GraphPad.
Ipr mice. Some were transferred to the QAC-use facility (ILSB) at weaning that constituted the QAC-exposed group (Figure 1C). Similar results were observed; QAC-exposed mice had significantly smaller spleens and RLNs, and a trending decrease of MLN-to-body weight ratio at the endpoint of 12 weeks of age (Figure 1D). We also repeated the second experiment for a different endpoint of 16 weeks of age; the differences were not statistically significant, but the trend was consistent (data not shown). Therefore, contrary to our initial hypothesis, ambient exposure to QACs decreased two hallmarks of lupus, splenomegaly and lymphadenopathy, in female MRL/lpr mice. We decided to focus on the spleen for mechanistic investigations.

Decreased Ex Vivo Migration and Chemotaxis of Neutrophils With Ambient Exposure to QACs

Neutrophils can shape SLE pathogenesis (37–39) and are one of the most abundant leukocytes in the bronchoalveolar lavage of inflamed airways following QAC exposure in mice (40). Neutrophils migrate and infiltrate lymphoid organs to modulate T-cell responses (41) that in turn facilitate SLE development (42). We compared the migratory capabilities of neutrophils isolated from the BM of QAC-exposed vs. QAC-free mice. We used a novel microfluidic chemotaxis platform (Figure S1), which allowed ex-vivo monitoring of the behavior of individual neutrophils while mimicking the mechanical confinement within animal tissues, and employed time-lapse imaging to measure the migration of BM-derived neutrophils. Competitive chemotaxis of neutrophils toward either the medium control or an inflammatory chemoattractant, LTB₄, was determined. The results showed that neutrophils from QAC-exposed mice had significantly less directional migration toward LTB₄ (Figures 2A, B). Notably, neutrophil from QAC-exposed mice exhibited a constantly low velocity of migration (Figure 2A), indicating that the maze on the microfluidic device might have hindered cell migration (Figure 2C); whereas neutrophils from QAC-free mice showed a sharp increase of velocity toward the LTB₄ during the first 150 min. No significant differences in non-directional migration was observed. Similar results were obtained for neutrophils isolated at either 12 weeks (Figure 2) or 16 weeks of age (Figure S3). These results suggest that neutrophils from QAC-exposed mice have decreased capabilities for chemotactic migration compared to those isolated from QAC-free mice.

Decreased Infiltration of Neutrophils “Into the Spleen” With Ambient Exposure to QACs

We hypothesized that with decreased migration and chemotaxis capabilities, fewer neutrophils would migrate from the BM to the spleen, leading to reduced splenomegaly. Therefore, we quantified neutrophils in splenic sections harvested from QAC-exposed vs. QAC-free MRL/lpr mice using flow cytometry. Both experimental settings gave us the same result. Using the 2nd experimental setting as an example, when compared to their littermates that stayed in the QAC-free environment, we found a trending reduction of Gr-1+ cells as a percentage of CD11b+CD11c− myeloid cells or total live cells in the spleen of QAC-exposed mice (Figure 3A; gating strategy can be found in Figure S6A). IHC staining of splenic sections targeting Ly6G, a neutrophil-specific marker, confirmed that there were fewer neutrophils (Figure 3B), as indicated by significantly lower integrated density scores of the PE fluorescence (Figure 3C), in the spleens of QAC-exposed mice.
Cytokines modulate leukocyte migration to the lymphoid organs and subsequently shape SLE pathogenesis (43, 44). In particular, chemotactic factors such as TNFα can promote neutrophil migration and their tissue influx (45, 46), and prevent their egression from the BM (47). Consistent with decreased neutrophil infiltration into the spleen, serum TNFα were significantly reduced in QAC-exposed mice (Figure 3D and Figure S4A). To induce cell mobilization from the BM, TNFα inhibits the production of stromal cell-derived factor 1 (SDF-1; also called CXCL12) and downregulate the retention of CXCR4-expressing cells (48). Therefore, a lower serum level of TNFα suggests higher SDF-1 in the BM and decreased cell mobilization. Upregulation of CXCR4 also leads to cell retention in the BM (49, 50). CXCR2, on the other hand, antagonizes the effect of CXCR4 on cell trafficking (51, 52). Interestingly, we found that BM-derived neutrophils from QAC-exposed mice had a significantly increased transcript level of CXCR4 (Figure 3E) and a slight trending reduction of CXCR2 (Figure S4B), resulting in a significant increase of their ratio (Figure 3F) when compared to QAC-free animals. This suggests increased retention of neutrophils in the BM with ambient QAC exposure, which is consistent with the decrease in splenic infiltration.

Together, these findings suggest that in a QAC-exposed environment, there was decreased infiltration of neutrophils into the spleen.

**Pro-Inflammatory Neutrophilic Phenotype With Ambient Exposure to QACs**

Next, we questioned whether neutrophils from QAC-exposed MRL/lpr mice not only failed to migrate, but were also anti-inflammatory. Surprisingly, transcript analysis of BM-derived neutrophils showed that those from QAC-exposed mice had a significantly increased pro-inflammatory profile (Figure 4). Significant upregulation of IL-6 expression in isolated neutrophils was detected with QAC.
exhibit a pro-inflammatory activity and chronicity scores (Figure S5A). Concerned that the pro-inflammatory neutrophils in QAC-exposed mice would lead to kidney dysfunction associated with lupus (37, 55, 56), we investigated the severity of glomerulonephritis. The result showed that mice in the QAC-exposed vs. QAC-free environment had similar levels of proteinuria (Figure S5A), in the kidneys of QAC-exposed mice. Renal inflammation activity and chronicity scores (Figure S5D), based on histopathological analysis of the kidneys (Figure S5E), did not significantly change with ambient QAC exposure.

These results suggest that while BM-derived neutrophils exhibit a pro-inflammatory phenotype in QAC-exposed mice, they did not exacerbate lupus-associated kidney inflammation.

**Reduced Expansion and Activation of Splenic T Cells With Ambient Exposure to QACs**

Neutrophils can either mitigate or accelerate SLE pathogenesis (37, 38). Pro-inflammatory neutrophils exhibit part of their pathogenic roles in SLE by infiltrating the lymphoid organs to prime pathogenic T cells (41, 42). However, with SLE progression, neutrophils also upregulate their expression of PD-L1, a programmed death ligand (57). PD-L1 expressing neutrophils contribute to T-cell exhaustion and inhibit the proliferation of T cells (41, 58, 59). Interestingly, we found more Gr-1+ myeloid cells in the BM positive for PD-L1 with QAC exposure (Figure 5A and Figure S6A). This was consistent with significantly upregulated expression of PD-L1 mRNA in isolated Ly6G+ neutrophils (Figure 5B). Indeed, in IHC-stained splenic sections of QAC-exposed mice, we found prominent upregulation and interaction between PD-L1 and PD-1 (Figure S6B; quantifications in Figures 5C, D). Further, we show co-localization of PD-L1, PD-1, Ly6G (neutrophils), and CD3 (T cells) with QAC exposure (Figure 5E).

Analysis of T cells revealed significantly fewer CD3+ in the spleen of QAC-exposed mice (Figure 5F). Although there was only a trending reduction of CD4+ as the percentage of CD3+ T lymphocytes (Figure S6C, P = 0.052) with QAC exposure, the percentage of CD8+ cells increased significantly (Figure 5G and Figure S6D). This resulted in a significantly reduced CD4/CD8 ratio for QAC-exposed splenocytes (Figure 5H). CD8+ T cells are generally considered protective in lupus, as depletion of CD8+ T cells in murine lupus through antibody neutralization or genetic knockout is associated with aggravated autoimmune progression (60–62). Thus, a reduced CD4/CD8 ratio is consistent with decreased splenomegaly with ambient QAC exposure. Moreover, the activation marker CD69 was significantly reduced on CD4+ T cells (Figure 5I) and double-negative (DN) T cells (Figure S6E). Furthermore, a significant percentage of splenic CD3+ cells from QAC-exposed mice were CD62L+CD44+ naïve T cells (Figure S6F), resulting in a significant increase of the ratio of naïve vs. effector T cells (Figure S6G).

Together, these results indicate reduced splenic T-cell expansion and activation in the ambient QAC-exposed environment that may have resulted from increased PD-L1:PDL-1 interaction between neutrophils and T cells.

**Increased Apoptosis of T Cells With Ambient Exposure to QACs**

QACs have been reported to significantly affect cell energetics and induce necrotic cell death (63). QAC-based cationic
surfactants have been shown to induce apoptosis in both normal and cancer cells (64). In addition, increased PD-L1 expression on neutrophils may lead to T-cell exhaustion (58, 59). Therefore, we sought to determine increased apoptosis as an additional mechanism for the reduction of splenomegaly. Indeed, we found increased apoptosis of splenic memory T cells with ambient QAC exposure. Central memory CD62L+ CD44+ TCM cells were at the early apoptotic stage as indicated by a significant increase of Annexin V+PI− cells (Figure 6A). Effector memory CD62L-CD44+ TEM cells, on the other hand, were in the late apoptotic stage (Figure 6B). Additionally, there was a significant increase in the ratio of early to late apoptotic TEM cells (Figure 6C). Similarly, we found a trending, nearly significant increase of both early apoptotic (P = 0.0549) and late apoptotic (P = 0.0547) DN T cells with QAC exposure (Figure 6D). Interestingly, there were significant reductions of serum (Figure 6E) and total splenic transcript (Figure 6F) levels of IL-6 with QAC exposure. IL-6 signaling can rescue T cells from apoptosis under both resting (65) and inflammatory (66) conditions. IL-6 also promotes T-cell survival through modulating the levels of anti-apoptotic factors (66, 67), and restricts activation-induced cell death of T cells via downregulating Fas/FasL signaling (68). Therefore, the reduction of serum and splenic IL-6 with QAC exposure is consistent with increased apoptosis of T cells.

To further evaluate the proliferation vs. apoptosis of splenic T cells, we stimulated them ex vivo using anti-CD3/anti-CD28. Although no difference in cell proliferation was noted after 3 days of stimulation (Figure S7A), significantly increased apoptosis of CD3+ T cells (Figure S7B) as well as CD4+ and CD8+ subpopulations (Figures S7C–E) were observed for splenocytes isolated from QAC-exposed mice. These results indicate increased apoptosis of splenic T cells with ambient QAC exposure, which might explain the decrease in splenomegaly.

DISCUSSION

The use of QACs has been correlated with the development of hypersensitivity responses (17, 18). This raises the concern that they may be related to autoimmunity dysregulations. However, whether exposure to QACs perturbs immune homeostasis and contributes to development of autoimmune diseases based on the general concept of hygiene hypothesis remains speculative. To our knowledge, very limited studies have investigated the effect of QACs on systemic immune response (17, 20, 21), and our research was the first to explore how QAC-exposure would affect systemic autoimmunity. We evaluated the effects of the ambient exposure to QACs on lupus as a model of systemic autoimmunity. We chose the classical murine lupus-prone model, MRL/lpr, where mice develop splenomegaly, lymphadenopathy, and glomerulonephritis similar to the manifestations in human SLE (69–72). Although we cannot...
was observed including IL-6, IL-1, and BAFF. However, the upregulation of BAFF was not associated with increased pathological roles in lupus pathogenesis (37, 74). Paradoxically, BM-derived neutrophils from the exposed mice exhibited a pro-inflammatory phenotype. Upregulated neutrophilic expression of different modulators known to aggravate adaptive immune dysregulations in SLE (55, 77, 78) was observed including IL-6, IL-1β, TNFα, and BAFF. However, the activated CD69+CD44+ T cells (79) and DN T cells (80, 81). Meanwhile, a significant increase of protective CD8+ T cells (60, 62) was observed. Moreover, there was a significant increase in the ratio of naive to effector T cells. These data suggest that neutrophils infiltrating the spleen might have adopted suppressive functions and hindered T-cell activation and expansion that together contribute to reduced splenomegaly in QAC-exposed mice. This notion is supported by the upregulated expression of PD-L1 on the neutrophils with QAC exposure. PD-L1 expression on neutrophils has been shown to suppress T-cell responses in different inflammatory milieu such as in tumorigenic niches (82). Indeed, we detected prominent upregulation and co-localization of PD-L1 and PD-1 on neutrophils and T cells, respectively, with QAC exposure. In addition, PD-1:PD-L1 signaling is associated with not only reduced expansion of T cells (83), but also increased T-cell apoptosis (84). Interestingly, we also observed increased apoptosis of effector T-cell populations in the splenocytes of QAC-exposed mice upon in vitro stimulation. This suggests that QAC-exposure may have hindered T-cell activation through neutrophilic PD-L1-induced signaling.

Importantly, apoptotic cells from QAC-exposed mice were found to be in the early apoptotic stages. We observed increased early apoptosis of splenic TCM cells without significant changes in the late apoptotic TCM cells. Early apoptosis is a signal for phagocytosis that does not provoke inflammatory responses (85). For apoptotic cells to provide signals for an autoimmune response, they would have to undergo late apoptotic stages in which cells lose their integrity allowing the leakage of cytosolic and nuclear contents that in turn activate immune cells (85, 86). Therefore, the pattern of apoptosis we observed in QAC-exposed mice (early > late) is consistent with less systemic inflammation as indicated by the reduction of serum IL-6 and TNFα.

Perturbation of immunological tolerance in SLE could be an outcome of many contributing factors, including defective apoptosis and/or increased proliferation of autoreactive...
immune cells (8–10, 69) and defective clearance of autoantigens or apoptotic products (22, 87). QACs have been previously reported to significantly affect cell energetics, inducing apoptosis and necrosis (22, 64). Therefore, the phenotype of reduced splenomegaly and lymphadenopathy, an indication of protection against a mouse model of SLE, with QAC exposure may be a result of neutrophil-mediated toning of T-cell proliferation and/or apoptosis. However, our findings also indicate that even ambient exposure to QACs could alter neutrophil and T-cell phenotypes, functions, and fate, raising concerns about the immunotoxicity of these chemicals.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The animal study was reviewed and approved by IACUC at Virginia Tech.

AUTHOR CONTRIBUTIONS

XL, CJ, and TH conceived the study. XL and LA designed the experiments. XC-P, QM, BS, and PD contributed to mouse dissection and sample collection. MM performed the neutrophil ex-vivo microfluidic migration assay, whereas SL and ML quantified the neutrophil ex-vivo microfluidic migration. RS and LX performed the measurement of QAC residues. KE performed histopathological scoring. LA analyzed the data. LA, XL, CJ, and TH wrote the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We thank Valerie A. McDonald for help with animal care, Melissa Maris for the use of Flow Cytometry Core Facility, and Kristi Decourcy for the use of Fralin Imaging Core Facility at Virginia Tech.

FUNDING

Funding was received from National Institute of Arthritis and Musculoskeletal and Skin Diseases. We also would like to acknowledge the following funding sources. Environmental Pathology and Toxicology Training Grant funded by the National Institute of Environmental Health Sciences (T32-ES007032) for supporting RP. Seguin. The National Institute of General Medical Sciences of the National Institutes of Health under award number R35GM133610 for supporting M Moarefian.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.575179/full#supplementary-material

REFERENCES

1. Giannico G, Fogo AB. Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol (2013) 8(1):138–45. doi: 10.2215/CJN.03400412
2. Teh CL, Phui VE, Ling GR, Ngu L-S, Wan SA, Tan CH-H. Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience. Clin Kidney J (2018) 11(1):56–61. doi: 10.1093/ckj/sfx063
3. Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol (2016) 12(12):716–724. doi: 10.1038/nrrheum.2016.186
4. Mehlokhg MA, Mehlokhg M. The clinical importance of lymphadenopathy in systemic lupus erythematosus. Acta Reumatol Portuguesa (2008) 33(4):402–6.
5. Smith LW, Petri M. Diffuse Lymphadenopathy as the Presenting Manifestation of SLE. J Clin Rheumatol: Pract Rep Rheum Musculoskeletal Dis (2013) 19(7):397. doi: 10.1097/RHU.0b013e3182afa924
6. Afzal W, Arab T, Ullah T, Teller K, Doshi KJ. Generalized lymphadenopathy as presenting feature of systemic lupus erythematosus: case report and review of the literature. J Clin Med Res (2016) 8(11):819. doi: 10.14740/jocmr2717w
7. Pieterse E, van der Vlag J. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol (2014) 5:164. doi: 10.3389/ fimmu.2014.00164
8. Rieux-Laucat F, Le Deist F, Hivroz CEA, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmune. Science (1995) 268(5215):1347–9. 0036-8075. doi: 10.1126/science.7539157
9. Fisher GH, Rosenberg FJ, Strauss SE, Dale JK, Middelton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell (1995) 81(6):935–46. doi: 10.1016/0026-0495(95)90013-6
10. Dowdell KC, Niemela JE, Price S, Davis J, Hornung RL, Oliveira JB, et al. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood (2010) 115(25):5164–9. doi: 10.1182/blood-2010-01-263145
11. Lockshin MD, Babhiai M, Izmirly P, Boyon JP, Crow MK. SLE: reconciling heterogeneity. Lupus Sci Med (2019) 6(1):e000280. doi: 10.1136/lupus-2018-000280
12. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (2011) 6(4):330–6.
13. Kamen DL. Environmental in autoimmunity. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood (2010) 115(25):5164–9. doi: 10.1182/blood-2010-01-263145
14. Mak A, Tay SH. Environmental factors, toxicants and systemic lupus erythematosus. Int J Mol Sci (2014) 15(9):16043–56. doi: 10.3390/ijms150916043
15. Gerba CP. Quaternary ammonium biocides: efficacy in application. Appl Environ Microbiol (2015) 81(2):464–9. doi: 10.1128/AEM.02633-14
16. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev (1999) 12(1):147–79. doi: 10.1128/CMR.12.1.147
17. Shane HL, Lukomska E, Stefanik AB, Anderson SE. Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyl(dimethylammonium) bromide. J Immunotoxicol (2017) 14(1):204–14. doi: 10.1080/1547691X.2017.1397826

Abdelhamid et al. Effects of QACs on Lupus

Frontiers in Immunology | www.frontiersin.org 9 October 2020 | Volume 11 | Article 575179
31. Liu X, Jegu J, Kopferschmitt MC, Donnay C, Hedelin G, Matzingler F, et al. Asthma among workers in healthcare settings: role of disinfection with quaternary ammonium compounds. *Clin Exp Allergy* (2014) 44(3):393–406. doi: 10.1111/cea.12215

32. Gonzalez M, Kopferschmitt M-C, Donnay C, Hedelin G, Velten M, Cantaine A, et al. Asthma and exposure to quaternary ammonium compounds in healthcare settings. *Eur Respir Rev* (2011) 20(121):393–406. doi: 10.1183/09059181.2011.121215

33. Munoz-Grajales C, Gonzalez LA, Alarcon GS, Acosta-Reyes J. Gender differences in systemic lupus erythematosus. *Rev Rad* (2020) 11:408. doi: 10.3389/fimmu.2019.00359

34. Liao X, Ren J, Wei C-H, Ross AC, Cecere TE, Jortner BS, et al. Paradoxical effects of all-trans-retinoic acid on lupus-like disease in the MRL/lpr mouse. *PLoS One* (2016) 11(10):e0163526. doi: 10.1371/journal.pone.0163526

35. Mu Q, Zhang H, Liao X, Lin K, Liu H, Edwards MR, et al. Control of lupus disease stage-dependent effects of all-trans-retinoic acid on lupus-like disease in the MRL/lpr mouse. *PLoS One* (2015) 10(3):e0118176. doi: 10.1371/journal.pone.0118176

36. Kaplan MJ, Neutrophils in the pathogenesis and manifestations of SLE. *Nat Rev Rheumatol* (2017) 13(12):691–9. doi: 10.1038/nrrheum.2017.132

37. Der E, Trugnanie A, Khan A, Jorgensen T. Pro- and anti-inflammatory neutrophils in lupus. *J Cell Immunol* (2014) 5(4):239. doi: 10.4172/2155-8999.1000239

38. Bird AK, Chang M, Barnard J, Goldberg BI, Meednu N, Rangel-Moreno J, et al. Neutrophil slow disease progression in Murine Lupus via modulation of autoreactive germal centers. *J Immunol* (2017) 199(2):458–66. doi: 10.4049/jimmunol.1700354

39. Larsen ST, Verder H, Nielsen GD. Airway effects of unaltered quaternary ammonium compounds in mice. *Basic Clin Pharmacol Toxicol* (2012) 110(6):537–43. doi: 10.1111/j.1742-7843.2011.00851.x

40. Castell SD, Harmann MF, Morin G, Malette RA, Pistoiesi-Palencia MC. Neutrophils which migrate to lymph nodes modulate CD4+ T cell response by a PD-1-dependent mechanism. *Front Immunol* (2019) 10:105. doi: 10.3389/fimmu.2019.00105

41. Cristip JC, Kytariss VC, Forchert C, Tsokos GC. T cells as therapeutic targets in SLE. *Nat Rev Rheumatol* (2010) 6(6):317. doi: 10.1038/nrrheum.2010.60

42. Davis LS, Huteson J, Mohan C. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. *J Interferon Cytokine Res* (2011) 31(10):781–9. doi: 10.1089/jir.2011.0047

43. Ohl K, Tenbrook K. Inflammatory cytokines in systemic lupus erythematosus. *BioMed Res Int* (2011) 2011:432595. doi: 10.1155/2011/432595

44. Lukacs NW, Stierer RM, Chensue SW, Widmer M, Kunel SK. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. *J Immunol* (1995) 154(10):5411–7.

45. Vieira S, Lemos H, Grespan R, Napimoga MH, Dal-Secco D, Freitas A, et al. A crucial role for TNF-α in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. *Br J Pharmacol* (2009) 158(3):779–89. doi: 10.1111/j.1476-5381.2009.00367.x

46. Jagels MA, Hugh T. Neutrophil chemotactic factors promote leukocytosis. A common mechanism for cellular recruitment from bone marrow. *J Immunol* (1997) 158(1):40–6.

47. Zhang Q, Guo R, Schwarz EM, Boyce BF, Xing L. TNF inhibits production of bone-stored cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood. *Arthritis Res Ther* (2008) 10(2):R37. doi: 10.1186/ar2391

48. Suratt BT, Petty JM, Young SK, Malcolm KC, Lieber JG, Nick JA, et al. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. *Blood* (2004) 104(2):565–71. doi: 10.1182/blood-2003-10-3638

49. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. *Blood Am Soc Hematol* (2009) 113(19):4711–9. doi: 10.1182/blood-2008-09-177287

50. Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. *J Clin Invest* (2010) 120(7):2423–32. doi: 10.1172/JCI41649

51. Martin C, Burdon PC, Bridger G, Gutierrez-Ramos J-C, Williams TJ, Rankin SM. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. *Immunity* (2003) 19(4):583–93. doi: 10.1016/S1074-7613(03)00263-2

52. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLYS member of the family of B lymphocyte stimulator. *Science* (1999) 285(5425):260–3. doi: 10.1126/science.285.5425.260

53. Smulski CR, Eibel H. BAFF and RANKL-Receptor in B Cell Selection and Survival. *Front Immunol* (2018) 9:2285. doi: 10.3389/fimmu.2018.02285

54. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFN. *J Immunol* (2010) 184(6):3284–97. doi: 10.4099/jimmunol.0902199

55. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Netting acid exerts disease-stage dependent effects on Pristane-induced lupus. *Dev Cell* (2015) 32(2):246–68. doi: 10.1016/j.devcel.2012.02.003

56. Mu Q, Zhang H, Liao X, Lin K, Liu H, Edwards MR, et al. Control of lupus nephritis by changes of gut microbiota. *Microbiome* (2017) 5(1):73. doi: 10.1186/s40168-017-0300-8

57. Liao X, Ren J, Wei C-H, Ross AC, Cecere TE, Jortner BS, et al. Paradoxical effects of all-trans-retinoic acid on lupus-like disease in the MRL/lpr mouse. *PLoS One* (2015) 10(3):e0118176. doi: 10.1371/journal.pone.0118176

58. Kaplan MJ, Neutrophils in the pathogenesis and manifestations of SLE. *Nat Rev Rheumatol* (2011) 7(12):691–9. doi: 10.1038/nrrheum.2011.132

59. De R, Trugnanie A, Khan A, Jorgensen T. Pro- and anti-inflammatory neutrophils in lupus. *J Cell Immunol* (2014) 5(4):239. doi: 10.4172/2155-8999.1000239

60. Bird AK, Chang M, Barnard J, Goldberg BI, Meednu N, Rangel-Moreno J, et al. Neutrophil slow disease progression in Murine Lupus via modulation of autoreactive germal centers. *J Immunol* (2017) 199(2):458–66. doi: 10.4049/jimmunol.1700354

61. Mozes E, Lovchik J, Zinger H, Singer D. MHC class I expression regulates susceptibility to spontaneous autoimmune disease in (NZBxNZW) F1 mice. *Lupus* (2005) 14(4):308–14. doi: 10.1191/09612305020790a
61. Adachi Y, Inaba M, Sugihara A, Koshiji M, Sugiru K, Amoh Y, et al. Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW x BXSB)F1 mice. *Immunochemistry* (1998) 35(4):451–64. doi: 10.1016/S0171-2895(98)80052-1

62. McPhee CG, Sprouls TJ, Shin DM, Bubier JA, Schott WH, Steinbuck MP, et al. MHC class I family proteins retard systemic lupus erythematosus autoimmunity and B cell lymphomagenesis. *J Immunol* (2011) 187(9):4695–704. doi: 10.4049/jimmunol.1101776

63. Inacio AS, Costa GN, Domingues NS, Santos MS, Moreno AJ, Vaz WL, et al. Mitochondrial dysfunction is the focus of quaternary ammonium surfactant toxicity to mammalian epithelial cells. *Antimicrobial Agents Chemotherapy* (2013) 57(6):2631–9. doi: 10.1128/AAC.02437-12

64. Enomoto R, Suzuki C, Ohano M, Ohasi T, Putagami R, Ishikawa K, et al. Cationic surfactants induce apoptosis in normal and cancer cells. *Ann N Y Acad Sci* (2007) 1095:1–6. doi: 10.1196/annals.1397.001

65. Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. *J Immunol* (1997) 158(12):5791–6.

66. Atreya R, Mudter J, Finotto S, Müller-Bergh J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. *Nat Med* (2000) 6(5):583–8. doi: 10.1038/75068

67. Hong C, Nam AS, Keller HR, Ligons DL, Park J-Y, H.-w. Yoon J, et al. and J.-H. J. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2 independent inhibition of Fas/fasL expression and cell death. *Blood J Am Soc Hematol* (1998) 92(11):4212–9. doi: 10.1182/blood.V92.11.4212.4234#42_4212_4219

68. Watanabe-Fukunaga R, Brannan CIII, Copeland NG, Jenkins NA, Nagata S. Interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in systemic lupus erythematosus mice. *Ann N Y Acad Sci* (2007) 1095:1–60. doi: 10.1126/science.75068

69. Watanabe-Fukunaga R, Brannan CII, Copeland NG, Jenkins NA, Nagata S. Interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in systemic lupus erythematosus mice. *Adv Rheumatol* (2011) 6:20651. doi: 10.1038/srep20651

70. Lopez, P. Rodriguez-Carrio J, Caminal-Montero L, Mozlo L, Suarez A. A pathogenic IFNalpha, BlyS and IL-17 axis in Systemic Lupus Erythematous patients. *Sci Rep* (2016) 6:20651. doi: 10.1038/srep20651

71. Peixoto TV, Carrasco S, Botte DAC, Catanoso S, Parra ER, Lima TM, et al. CD4(+)/CD69(+)/CD154(+) T cells and CD4(+)/CD25(+) FoxP3(+)/Treg cells imbalance in peripheral blood and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice. *Adv Rheumatol* (2019) 59(1):30. doi: 10.1186/s42358-019-0072-x

72. Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. *Curr Opin Rheumatol* (2017) 29(5):434. doi: 10.1097/BOR.0000000000000412

73. Rutala WA, Weber DJ. Disinfection, sterilization, and control of hospital ward. *Mandell Douglas Bennett’s Principles Pract Infect Dis* (2015) 3294–309.e4. doi: 10.1016/B978-1-4557-4801-3-00301-5

74. Gupta S, Kaplan MJ. The role of neutrophils and NETosis in autoimmune and renal diseases. *Nat Rev Nephrol* (2016) 12(7):402–13. doi: 10.1038/nrneph.2016.71

75. Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. *Curr Opin Rheumatol* (2015) 27(5):448–53. doi: 10.1097/BOR.000000000000197

76. Frangou E, Vassilopoulos D, Boletis J, Boumpas DT. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. *Autoimmun Rev* (2019) 18(8):751–60. doi: 10.1016/j.autrev.2019.06.011

77. Palanichamy A, Bauer JW, Yalavarthi S, Meednu N, Barnard J, Owen T, et al. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. *J Immunol* (2014) 192(3):906–18. doi: 10.4049/jimmunol.1302112

78. Abdelhamid et al. Effects of GAOs on Lupus

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Abdelhamid, Cabana-Puig, Mu, Mostafain, Swartwout, Eden, Das, Seguin, Xu, Lowen, Lavani, Hrubec, Jones and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, reproduction or distribution in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.